{'fraction_non_alphanumeric': 0.016913319238900635, 'fraction_numerical': 0.005285412262156448, 'mean_word_length': 5.912408759124087, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Correlation between abnormal baseline liver tests and long‐term clinical course in Hodgkin's disease

Studies used for evaluating the liver status of patients with Hodgkin's disease have been retrospectively examined for 137 consecutive patients with previously untreated Stage I‐II involvement. The minimum observation for all cases since initial treatment is 4 years, with a median risk interval of 6 years. Extension of Hodgkin's disease to the liver has seldom been noted in patients who presented with abnormal baseline liver studies. Instead, reversion of abnormal tests toward normal usually occurred after local lymphatic irradiation, suggesting an indirect effect of active Hodgkin's disease on hepatocellular function. This correlation of the laboratory tests with the clinical course emphasizes that diagnostic studies other than definitive biopsy should be interpreted conservatively, especially in terms of treatment decision‐making.